Last reviewed · How we verify
PD-1 inhibitors plus lenvatinib
At a glance
| Generic name | PD-1 inhibitors plus lenvatinib |
|---|---|
| Also known as | Non |
| Sponsor | Chen Xiaoping |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion
- Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer (PHASE2)
- Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer (PHASE2)
- Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO) (PHASE2)
- A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC (PHASE2)
- Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
- Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification (PHASE2)
- HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PD-1 inhibitors plus lenvatinib CI brief — competitive landscape report
- PD-1 inhibitors plus lenvatinib updates RSS · CI watch RSS
- Chen Xiaoping portfolio CI